Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 16;11(1):5225.
doi: 10.1038/s41467-020-19095-z.

Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits

Julia Böhme  1 , Nuria Martinez  2 , Shamin Li  1   3 , Andrea Lee  1 , Mardiana Marzuki  1 , Anteneh Mehari Tizazu  1 , David Ackart  4 , Jessica Haugen Frenkel  4 , Alexandra Todd  4 , Ekta Lachmandas  5 , Josephine Lum  1 , Foo Shihui  1 , Tze Pin Ng  6 , Bernett Lee  1 , Anis Larbi  1 , Mihai G Netea  5   7 , Randall Basaraba  4 , Reinout van Crevel  5 , Evan Newell  1   3 , Hardy Kornfeld  2 , Amit Singhal  8   9   10   11
Affiliations

Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits

Julia Böhme et al. Nat Commun. .

Abstract

Patients with type 2 diabetes (T2D) have a lower risk of Mycobacterium tuberculosis infection, progression from infection to tuberculosis (TB) disease, TB morality and TB recurrence, when being treated with metformin. However, a detailed mechanistic understanding of these protective effects is lacking. Here, we use mass cytometry to show that metformin treatment expands a population of memory-like antigen-inexperienced CD8+CXCR3+ T cells in naive mice, and in healthy individuals and patients with T2D. Metformin-educated CD8+ T cells have increased (i) mitochondrial mass, oxidative phosphorylation, and fatty acid oxidation; (ii) survival capacity; and (iii) anti-mycobacterial properties. CD8+ T cells from Cxcr3-/- mice do not exhibit this metformin-mediated metabolic programming. In BCG-vaccinated mice and guinea pigs, metformin enhances immunogenicity and protective efficacy against M. tuberculosis challenge. Collectively, these results demonstrate an important function of CD8+ T cells in metformin-derived host metabolic-fitness towards M. tuberculosis infection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Metformin-educated CD8+ T cells protect against M. tuberculosis.
a Experimental strategy and assessed readouts. b, c Bacterial load in the lung of recipient mice 21 days post transfer, from two different experiments. No transfer—Irradiated recipients that did not receive any cells. Metformin-educated—CD4+ or CD8+ cells from donor mice treated with metformin; Control—cells from untreated mice. n = 5–6 mice/group/experiment. d Flow cytometric analysis of splenic CD8+ T cells from mice of experiment 1 b. TM - memory T cells, CD44+CD62L+; TE effector T cells, CD44+CD62L−; TN - naive T cells, CD44−CD62L+. e Frequency and number of CD8+ TE, TM, and TN cells in the recipient mice of experiment 1. n = 5 mice/group. f Frequency and number of IFNγ+, TNF+, or Perforin+ CD8+ TM cells from e. n = 5 mice/group. g Frequency and number of IFNγ+ and/or Perforin+ CD45.1+CD8+ TM cells in the recipient mice of experiment 2. n = 5 mice per group. Box-and-whisker plots show the median, 5 and 95 percentiles. All data are analyzed using Kruskal–Wallis test with Dunn’s multiple comparison.
Fig. 2
Fig. 2. Metformin treatment expands CD8+CXCR3+ TM cell population in spleen and lungs of mice.
a Experimental set-up of in vivo experiments. b Visualized t-SNE map of CD8+ T cells from spleen of wild-type (WT) mice with automated cluster gating. t-SNE was performed on live CD45+CD90+TCRαβ+CD4−CD8+ cells after gating out B cells. c Normalized expression intensities of indicated marker was calculated and overlaid on the t-SNE plot, characterizing all clusters of CD8+ T cells in spleen. Means ± SD of four mice per group, one-tailed Mann–Whitney U test. d Manual gating analysis of CD8+CXCR3+ TM cells in control and metformin-treated WT mice. e, f Flow cytometric analysis of splenic CD8+ T-cell subsets from control and metformin-treated WT mice. Pooled data from three independent experiments. Means ± SD of n = 13–15 mice per group, two-tailed Mann–Whitney U test. g Heat map displaying frequency of various surface markers in lung CD8+ T cells of control and metformin-treated WT mice. n = 4. *p ≤ 0.05 by two-tailed paired t test. h Flow cytometric analysis of spleen CD8+ TE, TM, and TN cells of control and metformin-treated Cxcr3−/− mice. Data shown one out of two experiments, mean ± SD of five mice per group. i Left—volcano plot showing DEGs from RNA sequencing data of CD8+ T cells from Cxcr3−/− and WT mice. n = 5 mice/group. Right—Canonical pathway enrichment via Ingenuity pathway analysis (IPA) of 202 DEGs. j Heat map displaying the expression level of 35 FOXO1 targets in data shown in i. NS not significant.
Fig. 3
Fig. 3. Metformin promotes CD8+ T-cell SRC, mitochondrial mass, survival, and FAO.
a Oxygen consumption rate (OCR) and spare respiratory capacity (SRC) in spleen CD8+ T cells from control and metformin-treated WT mice in response to different drugs. n = 4 control mice, n = 5 metformin-treated mice. b OCR in spleen CD8+ T cells from control and metformin-treated Cxcr3−/− mice. n = 6 mice/group. c Mitotracker green staining of CD8+ T cells from control and metformin-treated WT mice. MFI - median fluorescence intensity. n = 4 mice/group. d TMRM staining of CD8+ T cells from control and metformin-treated WT mice. n = 4 mice/group. e Experimental schematic of adoptive transfer of CD8+ T cells into congenic WT mice. f Frequency of CD45.1+ cells in the spleen and lymph node of recipient mice. n = 4 mice/group. g OCR in spleen CD8+ T cells from control and metformin-treated WT mice in response to different drugs under low glucose (LG) condition in the presence and absence of palmitate. n = 5 mice/group. h, i OCR in spleen CD8+ T cells from metformin-treated WT mice in response to different drugs under LG condition in the presence of palmitate. h n = 5 mice/group; i n = 8 mice/group. j Glucose uptake (2-NBDG) in CD8+ TM cells, analyzed by flow cytometry. n = 5 mice/group. Data in a, c, d, f, g, and j are presented as mean ± SD, two-tailed Mann–Whitney U test.
Fig. 4
Fig. 4. Metformin reprograms gene expression of CD8+ TM cells.
a Schematic depicting sorting of CD8+ TM cells for RNA sequencing and identification of DEGs in metformin-educated CD8+ TM cells. b Molecular function enrichment via Ingenuity pathway analysis (IPA) of DEGs in a. c Heat map displaying the expression level of 86 genes related to cell death and survival. d Flow cytometric analysis of caspase-1 in splenic CD8+ T cells from Mtb-infected mice treated or not with metformin. n = 5 mice/group. e Experimental set-up for the transfer of CD8+ TM or TE cells into TCRβδ−/− mice followed by Mtb or BCG infection. Three experiments were performed. f, g Flow cytometric analysis of the frequency of CD45.1+ lung f and splenic g cells in recipient mice. n = 4 control group, n = 6 metformin group. h Bacterial load in the lung of Mtb-infected TCRβδ−/− recipient mice. i, j Bacterial load in the lung of BCG-infected TCRβδ−/− recipient mice. Data of mean ± SD of 4–5 mice per group, Kruskal–Wallis test with Dunn’s multiple correction. Data in d, f, g, and h is presented as mean ± SD, two-tailed Mann–Whitney U test.
Fig. 5
Fig. 5. Metformin promotes BCG vaccine immunogenicity and efficacy.
a PPD-specific response of spleen cells, analyzed by flow cytometry. Data on IFNγ producing CD8+ T, TM, and TE cells. n = 5 mice/group. Box-and-whisker plot show the median, 5 and 95 percentiles, one-way ANOVA with Turkey’s multiple comparison test. b, c Mitotracker green b TMRM c staining of splenic CD8+ T cells from control and metformin-treated BCG-vaccinated WT mice. b n = 4 mice/group; c n = 5 mice/group. means ± SD, Mann–Whitney U test. d Changes in gene expression in CD8+ TM cells from BCG-vaccinated mice treated or not with metformin. IPA analysis of 607 DEGs. n = 5 mice/group. e Schematic of Mtb infection of metformin-treated BCG-vaccinated mice. Lung bacillary load at 30 days post infection (p.i) is shown. n = 6 mice/group. f Schematic of Mtb infection of metformin-treated unvaccinated and BCG-vaccinated guinea pigs. g Lung bacillary load in unvaccinated and BCG-vaccinated Mtb-infected guinea pigs treated or not with metformin. n = 6–7 animals/group. h Light micrographs of hematoxylin and eosin (H&E) staining of lung sections from animals in g. Magnification for main image ×40 (scale bars, 50 μm) and insert ×100. i Morphometric analysis of lung sections shown in h indicating the mean lesion lung involvement from each guinea pig. n = 6–7 animals/group. Data in a–c, e is representative of two independent experiments. Guinea pig data in g and i is from one experiment. Data in e, g, and i, means ± SD, Kruskal–Wallis test with Dunn’s multiple correction.
Fig. 6
Fig. 6. Metformin treatment expands CD8+CXCR3+ TM cell population in humans.
a Strategy of analyzing PBMCs from metformin-treated healthy individuals. b t-SNE map of human peripheral CD8+ T cells with manually cluster gating for TE, TM, and TN cells. c Normalized expression intensities of indicated markers were calculated and overlaid on the t-SNE plot, characterizing all cluster of human CD8+ T cells. d Manual gating identified differential expression of CD127 and CXCR3, distinguishing two CD8+ TM subpopulations, TM1 and TM2. e Frequency of CD8+CD127+CXCR3+ TM cells before and after metformin treatment. n = 8 subjects, analysis by Wilcoxon matched-pairs signed rank test. f Overlay plot showing expression of BCL2 in CD8+CD127+CXCR3- and CD8+CD127+CXCR3+ TM cells. BCL2 expression in CD8+ TN cells is also indicated. Data shown from one representative donor. g Flow cytometric analysis of frequency of peripheral CD8+CXCR3+ TM cells in T2D patients receiving either metformin or other diabetic monotherapy, n = 18 other monotherapy group, n = 42 metformin group. Box-and-whisker plot show the median, 5 and 95 percentiles. Analysis by two-tailed t test with Welch’s correction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat. Rev. Immunol. 2015;15:255–263. doi: 10.1038/nri3813. - DOI - PubMed
    1. Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat. Rev. Drug Disco. 2018;17:35–56. doi: 10.1038/nrd.2017.162. - DOI - PMC - PubMed
    1. Singhal A, et al. Metformin as adjunct antituberculosis therapy. Sci. Transl. Med. 2014;6:263ra159. doi: 10.1126/scitranslmed.3009885. - DOI - PubMed
    1. Magee, M. J., Salindri, A. D., Kornfeld, H. & Singhal, A. Reduced prevalence of latent tuberculosis infection in diabetes patients using metformin and statins. Eur. Respir. J.53, 1801695 (2019). - PMC - PubMed
    1. Pan SW, et al. The risk of TB in patients with type 2 diabetes initiating metformin vs sulfonylurea treatment. Chest. 2018;153:1347–1357. doi: 10.1016/j.chest.2017.11.040. - DOI - PubMed

Publication types

MeSH terms